Everolimus
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Sarcoma
Conditions
Progressive Sarcoma
Trial Timeline
Mar 31, 2008 → May 17, 2017
NCT ID
NCT00767819About Everolimus
Everolimus is a phase 2 stage product being developed by Novartis for Progressive Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00767819. Target conditions include Progressive Sarcoma.
What happened to similar drugs?
2 of 20 similar drugs in Progressive Sarcoma were approved
Approved (2) Terminated (4) Active (14)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00655252 | Pre-clinical | Completed |
| NCT05108740 | Pre-clinical | Completed |
| NCT05252585 | Approved | Active |
| NCT03525834 | Approved | Completed |
| NCT02962414 | Phase 3 | Active |
| NCT02842749 | Approved | Completed |
| NCT02429869 | Approved | Completed |
| NCT02539459 | Phase 2 | Terminated |
| NCT02687958 | Phase 2 | UNKNOWN |
| NCT02376985 | Phase 3 | Completed |
| NCT02338609 | Approved | Completed |
| NCT02236572 | Phase 2 | Terminated |
| NCT02273752 | Phase 2 | Terminated |
| NCT02201212 | Phase 2 | Completed |
| NCT01864070 | Phase 1 | Withdrawn |
| NCT01997255 | Phase 2 | Withdrawn |
| NCT02096107 | Approved | Completed |
| NCT02017860 | Phase 2 | Completed |
| NCT01636466 | Phase 3 | Terminated |
| NCT01609673 | Pre-clinical | Terminated |
Competing Products
20 competing products in Progressive Sarcoma